Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13415333 | 0.98 | DRD4 (0.40) | DRD4PDE3BPDE3APDE2APDE1A | |
| SCHEMBL22604338 | 0.98 | DRD4 (0.40) | DRD4PDE3BPDE3APDE2APDE1A | |
| SCHEMBL13326541 | 0.95 | — | — | |
| SCHEMBL12082578 | 0.78 | GRM5 (0.41) | DRD4GRM5 | |
| SCHEMBL3516499 | 0.77 | HTR2C (0.39) | DRD4GRM5KDM4E | |
| SCHEMBL23161482 | 0.72 | PDE3B (0.33) | PDE3BPDE3APDE2APDE1APDE1B | |
| SCHEMBL8316966 | 0.72 | MAOA (0.36) | DRD4GRM5CYP1A2 | |
| SCHEMBL18348345 | 0.72 | PDE3B (0.33) | PDE3BPDE3APDE2APDE1APDE1B | |
| SCHEMBL15723732 | 0.72 | PDE3B (0.33) | PDE3BPDE3APDE2APDE1APDE1B | |
| SCHEMBL14722498 | 0.71 | ALDH1A1 (0.43) | GAACYP1A2POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6433166-B1 | — | — | None | — | — | US | claimed |
| EP-1167350-B1 | Process for producing epsilon-caprolactam | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | claimed |
| EP-1016658-B1 | Process for producing E-caprolactam | SUMITOMO CHEMICAL CO (JP) | 2005-12-14 | — | — | EP | claimed |
| US-6433166-B2 | Process for producing ε-caprolactam | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | claimed |
| US-20020010329-A1 | Process for producing epsilon-caprolactam | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-24 | — | — | US | claimed |
| EP-1167350-A1 | Process for producing epsilon-caprolactam | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-02 | — | — | EP | claimed |
| US-6252068-B1 | CRYSTALLIZATION; HYDROGENATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-26 | — | — | US | claimed |
| EP-1016658-A2 | Process for producing E-caprolactam | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2000-07-05 | — | — | EP | claimed |
| US-6433166-B1 | — | — | None | — | — | US | disclosed |
| EP-4602024-A1 | PROCESS FOR PRODUCING HEXAMETHYLENEDIAMINE FROM CAPROLACTAM | Ascend Performance Materials Operations LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1016658-B1 | Process for producing E-caprolactam | SUMITOMO CHEMICAL CO (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-6433166-B2 | Process for producing ε-caprolactam | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20020010329-A1 | Process for producing epsilon-caprolactam | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-1167350-A1 | Process for producing epsilon-caprolactam | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1016658-A2 | Process for producing E-caprolactam | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | DRD4 966/4885PDE3B 2706/4885PDE3A 2518/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | DRD4 1617/4885PDE3B 2979/4885PDE3A 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.